Skip to main content

Table 2 Severity factors in patients with anti-HMGCR myopathy and successful steroid-based induction therapy, stratified by concomitant use of IVIG therapy and early vs late remission (N = 41)

From: Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

 Dual steroids/SSI cohort (n = 19)Triple steroids/IVIG/SSI cohort (n = 22)
Early remission (≤ 3 months), n = 10Late remission (> 3 months), n = 9Early remission (≤ 3 months), n = 12Late remission (> 3 months), n = 10
Weakness at treatment onset, n (%)8 (80)8 (89)11 (92)10 (100)
Age at treatment onset, median (range) years70.6 (59.9–83.6)69.4 (50.1–81.3)73.6 (46.5–83.1)60.4 (44.0–74.3)
CK level at treatment onset, median (range) UI/L2673 (696–12,000)6405 (3573–10,465)7317 (1556–13,339)10,789 (2267–23,000)
Severity score, mean (SD)1.4 (0.8)2.5 (0.9)2.5 (1.2)3.3 (0.9)
Severity score ≥ 3, n (%)1 (10)4 (44)6 (50)8 (80)
Delay from first increased serum CK (> 500 UI/L) to treatment, median (range) months1.4 (0–79.2)13.4 (0–24.9)0.8 (0–42.2)11.5 (0–95)
Delay from treatment to serum CK < 500 UI/L, median (range) months1.7 (0.4–3)11.5 (4–50.7)2.0 (0.6–3)15.0 (3.2–53)
Needed induction strategies to obtain remission, n (%)
 110 (100)8 (89)12 (100)6 (60)
 201 (11)01 (10)
 30002 (20)
 ≥ 40001 (10)
Successful maintenance with SSI monotherapy, n (%)8 (80)8 (89)5 (42)2 (20)
Corticosteroid dosage at last follow-up
 No corticosteroids8 (80)8 (89)9 (75)8 (80)
 Prednisone ≤ 5 mg per day2 (20)1 (11)1 (8)1 (10)
 Prednisone > 5 mg per day002 (17)1 (10)
Drug-free remission, n (%)3 (30)1 (11)00
Normal strength at last follow-up, n (%)9 (90)8 (89)6 (50)5 (50)
  1. SSI steroid-sparing immunosuppressant